Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study

F. Greden, John; V. Parikh, Sagar; J. Rothschild, Anthony; E. Thase, Michael; W. Dunlop, Boadie; DeBattista, Charles; R. Conway, Charles; P. Forester, Brent; M. Mondimore, Francis; C. Shelton, Richard; Macaluso, Matthew; Li, James; Brown, Krystal; Gilbert, Alexa; Burns, Lindsey; Jablonski, Michael; Dechairo, Bryan

doi:10.1016/j.jpsychires.2019.01.003

Public

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study

Published in Journal of Psychiatric Research • Jan 4, 2019

Authors:

John F. Greden

Sagar V. Parikh

Anthony J. Rothschild

Abstract

Current prescribing practices for major depressive disorder (MDD) produce limited treatment success. Although pharmacogenomics may improve outcomes by identifying genetically inappropriate medications, studies to date were limited in scope. Outpatients (N = 1167) diagnosed with MDD and with a patien...

Subject

Medicine

Randomized controlled trial

Major depressive disorder

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!